First Time Loading...

PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS

Watchlist Manager
PhaseBio Pharmaceuticals Inc Logo
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Watchlist
Price: 0.04 USD 5.26% Market Closed
Updated: May 5, 2024

PhaseBio Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PhaseBio Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Revenue
$10.8m
CAGR 3-Years
153%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

PhaseBio Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
PhaseBio Pharmaceuticals Inc

Not Available

Breakdown by Segments
PhaseBio Pharmaceuticals Inc

Total Revenue: 10.8m USD
100%
Sublicense Revenue: 10.8m USD
100%
License: 10.2m USD
94.4%
Development And Regulatory Services: 608k USD
5.6%

See Also

What is PhaseBio Pharmaceuticals Inc's Revenue?
Revenue
10.8m USD

Based on the financial report for Dec 31, 2021, PhaseBio Pharmaceuticals Inc's Revenue amounts to 10.8m USD.

What is PhaseBio Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
153%

Over the last year, the Revenue growth was 3 285%. The average annual Revenue growth rates for PhaseBio Pharmaceuticals Inc have been 153% over the past three years .